ESSA Pharma Inc
NASDAQ:EPIX

Watchlist Manager
ESSA Pharma Inc Logo
ESSA Pharma Inc
NASDAQ:EPIX
Watchlist
Price: 1.61 USD -1.23%
Market Cap: 71.5m USD
Have any thoughts about
ESSA Pharma Inc?
Write Note

ESSA Pharma Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ESSA Pharma Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
ESSA Pharma Inc
NASDAQ:EPIX
Accrued Liabilities
$897.5k
CAGR 3-Years
-29%
CAGR 5-Years
35%
CAGR 10-Years
N/A
B
Bright Minds Biosciences Inc
CNSX:DRUG
Accrued Liabilities
CA$42k
CAGR 3-Years
50%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Accrued Liabilities
$47.9m
CAGR 3-Years
20%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Covalon Technologies Ltd
XTSX:COV
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Spectral Medical Inc
TSX:EDT
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ESSA Pharma Inc
Glance View

Market Cap
71.5m USD
Industry
Biotechnology

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

EPIX Intrinsic Value
8.8 USD
Undervaluation 82%
Intrinsic Value
Price

See Also

What is ESSA Pharma Inc's Accrued Liabilities?
Accrued Liabilities
897.5k USD

Based on the financial report for Sep 30, 2024, ESSA Pharma Inc's Accrued Liabilities amounts to 897.5k USD.

What is ESSA Pharma Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
35%

Over the last year, the Accrued Liabilities growth was -39%. The average annual Accrued Liabilities growth rates for ESSA Pharma Inc have been -29% over the past three years , 35% over the past five years .

Back to Top